Is VK2735 FDA-approved?

No. VK2735 is investigational: it's being studied in clinical trials and isn't FDA-approved for any use.

Checked 1 Nov 2026. The sources are below.

VK2735

Also: VK-2735, VK 2735

Status label in the Peptimes Library
Phase 3 Trials
Routes in Peptimes
SubcutaneousOral
Updated
1 Nov 2026

US regulatory status

  • FDA status

    Not FDA-approved for any use. Drugs@FDA lists no application with VK2735 as an active ingredient.

    Source: Drugs@FDA, checked 1 Nov 2026

  • Investigational

    Yes.

    Source: ClinicalTrials.gov, checked 1 Nov 2026

How to track it in Peptimes

Add VK2735 in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Phase 3 Trials”, which describes its investigational status. It isn’t an approval.

  • Routes: subcutaneous or oral. Choose the one that matches each dose.
  • Logging: the amount you took, the route and how you feel.
  • Injection sites: subcutaneous doses record the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next. Oral doses skip this step.
  • Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.

Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell VK2735 or any other compound.

More sources

  • NIH, ClinicalTrials.gov, VANQUISH 1 (NCT07104500), checked 1 Nov 2026: a Phase 3 study of VK2735 sponsored by Viking Therapeutics, active, not recruiting.
  • NIH, ClinicalTrials.gov, studies of VK2735, checked 1 Nov 2026: registered studies, including Phase 3 studies of an injected and an oral form.
  • FDA, Drugs@FDA, checked 1 Nov 2026: no application lists VK2735 as an active ingredient.

Coming soon to the App Store

Coming soon to Google Play

See planned pricing